rdf-syntax-grammar
mods:
  schema location: http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
  title info:
    title: Immunotherapy
  name:
    name part: Naing, Aung.
    role:
      role term: editor.
    role:
      role term: edt
    role:
      role term: http://id.loc.gov/vocabulary/relators/edt
  name:
    name part: Hajjar, Joud.
    role:
      role term: editor.
    role:
      role term: edt
    role:
      role term: http://id.loc.gov/vocabulary/relators/edt
  name:
    name part: SpringerLink (Online service)
  type of resource: text
  genre: Electronic books.
  origin info:
    place:
      place term: sz
    date issued: 2021
    edition: 4th ed. 2021.
    issuance: monographic
  language:
    language term: eng
  physical description:
    reformatting quality: access
    form: remote
    extent: 1 online resource (VIII, 447 pages 41 illustrations, 32 illustrations in color)
  abstract: The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of Immunotherapy provides the most current overview of immuno-oncology in different cancer types and toxicities associated with immunotherapy. While immunotherapy has revolutionized the treatment landscape of several solid malignancies, several challenges still exist. Only a subset of patients derive clinical benefits; some do not respond at all, and others respond initially, only for their disease to progress later. Because these drugs can activate a broad range of immune cells, patients suffer from a unique set of side effects known as immune-related adverse events. As more immunotherapeutic agents are used in the clinic, it is important to provide updates about current and ongoing developments in the field to further research efforts and inform treatment decisions. The fourth edition will have a new focus on strategies to overcome the challenges associated with immunotherapy. Chapters will discuss topics such as biomarkers of response, resistance mechanisms, role of imaging in predicting immune-related adverse events, and management of immune-related adverse events. Written by leading experts conducting cutting-edge research, readers will gain up-to-date knowledge on the current state and future of immunotherapy. .
  table of contents: Immune System in Action -- 2. Resistance to Immunotherapy: Mechanisms and Means for Overcoming -- 3. Immunotherapy for Melanoma -- 4. Immunotherapy in Lung Cancer: Are the promises of long-term benefit finally met? -- 5. Landscape of Immunotherapy in Genitourinary Malignancies -- 6. Immuno-oncology for Gynecologic Malignancies -- 7. Immunotherapy for Neuro-oncology -- 8. Immunotherapy in Gastrointestinal Malignancies -- 9. An update on immune based therapies in acute myeloid leukemia: 2021 and beyond! -- 10. CAR T-cells -- 11. Skin Reactions to Immune Checkpoint Inhibitors -- 12. Immunotherapy Mediated luminal Gastrointestinal toxicities -- 13. Hepatobiliary and Pancreatic Adverse Events -- 14. Pulmonary toxicities of immunotherapy -- 15. Immune checkpoint inhibitors (ICIs) related cardiotoxicity -- 16. Renal Toxicity -- 17. Immune-Related Oral, Otologic and Ocular Adverse Events -- 18. Neurologic Toxicities of Immunotherapy -- 19. Cancer Imaging in Immunotherapy. .
  note: edited by Aung Naing, Joud Hajjar.
  subject:
    topic: Immunotherapy
  subject:
    topic: Cancer-Treatment
  subject:
    topic: Tumors-Immunological aspects
  subject:
    topic: Tumor markers
  subject:
    topic: Immunotherapy
  subject:
    topic: Cancer Therapy
  subject:
    topic: Tumour Immunology
  subject:
    topic: Tumour Biomarkers
  classification: RM270-282
  classification: 615.37
  classification: 571.96
  related item:
    title info:
      title: Springer Nature eBook
  related item:
    title info:
      title: Advances in Experimental Medicine and Biology, 1342
  identifier: 9783030793081
  identifier: http://proxy.library.tamu.edu/login
  record info:
    record creation date: 211220
    record change date: 20230330185027.4
    record identifier: in00004556361